Charles Wang | Epigenomics | Distinguished Scientist Award

Published on by Cell Biologist

Prof. Charles Wang | Epigenomics | Distinguished Scientist Award

Prof. Charles Wang | Loma Linda University Center for Genomics | United States

Dr. Changhong Wang (now known as Dr. C. Wang), a U.S. citizen, is a distinguished molecular toxicologist and genomic scientist currently serving as Director and Tenured Professor at the Center for Genomics, Loma Linda University. Originally from China, Dr. Wang holds dual graduate degrees in Public Health and Toxicology from Tongji Medical University and the University of Washington, respectively. His early career laid the foundation for pivotal research into environmental toxicants and gene-environment interactions. Dr. Wang has significantly contributed to the understanding of xenobiotic metabolism, DNA methylation, and the transgenerational effects of toxins and epigenetics. His leadership in molecular genetics research is reflected in numerous peer-reviewed publications and competitive grants. A passionate educator and mentor, Dr. Wang’s work bridges foundational science and clinical application, marking him as a strong contender for the Research for Distinguished Scientist Award.

Publication Profile: 

Socpus

Education:

Dr. Wang received his Ph.D. in Toxicology from the University of Washington, Seattle. His doctoral work focused on aflatoxin metabolism and liver glutathione S-transferases in nonhuman primates, mentored by Dr. David L. Eaton. Prior to that, he earned an MPH in Environmental Epidemiology from Tongji Medical University, China, where he developed a foundation in public health and environmental sciences. His dual training in toxicology and epidemiology provided a unique cross-disciplinary approach to health sciences. This strong academic background enables Dr. Wang to address critical questions regarding how environmental exposures affect human health, especially through epigenetic and genomic pathways. His educational path reflects a continuous pursuit of scientific excellence and translational impact, positioning him to bridge molecular discoveries with public health relevance—a crucial quality for a candidate of the Distinguished Scientist Award.

Experience:

Dr. Wang currently serves as Director and Tenured Professor at the Center for Genomics, School of Medicine, Loma Linda University (LLU), where he has led translational and mechanistic genomic research. His responsibilities span academic leadership, mentorship, and collaborative research within the Division of Molecular Genetics. Prior to this, he held the role of Associate Professor-Adjunct in Microbiology & Molecular Genetics at LLU. His earlier roles include postdoctoral and research scientist positions at institutions where he investigated environmental carcinogens, drug metabolism, and gene expression. Over three decades, Dr. Wang has built a multidisciplinary portfolio in toxicology, environmental health, and genomics. He is a leading voice in DNA methylation, epigenetic inheritance, and cancer biology. His integrative research style and administrative skills have allowed him to create impactful programs that foster innovation and interdisciplinary collaboration—an essential trait for any distinguished scientist.

Awards and Honors:

Dr. Wang’s academic journey has been decorated with prestigious accolades from the outset. He received the Excellent Medical Student Award  and Distinguished Graduate Student Award from Tongji Medical University. His pioneering research at the University of Washington earned him the First-Place Graduate Award for Research Excellence from the Society of Toxicology in New Orleans. He was awarded multiple Student Travel Awards from the University of Washington’s School of Public Health. These early recognitions underscore his long-standing commitment to scientific excellence and innovation. Dr. Wang’s later career has been marked by continuous success in publication, grant acquisition, and institutional leadership. These honors reflect both peer recognition and academic merit, reinforcing his status as a credible and outstanding candidate for the Research for Distinguished Scientist Award.

Research Focus:

Dr. Wang’s research focuses on environmental toxicology, genomics, and epigenetics, particularly in the context of transgenerational health effects. He investigates how toxicants such as cadmium, aflatoxin B1, and p,p’-DDE affect gene regulation through epigenetic reprogramming. His lab has pioneered work on DNA methylation, histone modifications, and miRNA signatures in diseases like cancer, neurodevelopmental disorders, and diabetes. Recent work has addressed the effects of e-cigarette exposure on neonatal brain methylomes and the epigenetic inheritance of addiction vulnerability. Dr. Wang also explores copy number variation and drug resistance mechanisms in oncology, using cutting-edge tools like single-cell RNA sequencing and patient-derived models. His integrative, multi-omics approach allows for deep mechanistic insights and clinical translation. His ability to lead multidisciplinary teams in high-impact research areas demonstrates both visionary thinking and the technical prowess necessary for distinguished scientific leadership.

Publications Top Notes:

  1. Cadmium-induced negative calcium balance in multiparous birth women

  2. Effect of cadmium on bone calcium in nonpregnant mice: Direct evidence on bone

  3. Cadmium’s impact on bone calcium in mouse dams: Itai-Itai-like syndrome model

  4. Induction of drug-metabolizing enzymes by BHA, ethoxyquin, and oltipraz

  5. Diquat and ciprofibrate effects on hepatic enzyme expression

  6. Mu-class GSTs mediate aflatoxin B1 epoxide conjugation in Macaca liver

  7. CYP1B1 expression analyzed in human tissues via hybridization techniques

  8. Cloning and characterization of alpha-class GSTs from Macaca liver

  9. Proteomic comparison of hepatocyte preparation methods

  10.  CYP3A41B polymorphism linked to puberty onset and breast cancer risk*

Conclusion:

In conclusion, Dr. Wang’s long-standing academic excellence, innovative research in toxicogenomics, and his leadership in advancing our understanding of environmental and epigenetic factors in disease clearly distinguish him as an outstanding scientist. His achievements fulfill and surpass the expectations for the Research for Distinguished Scientist Award. His profile reflects not only a deep commitment to rigorous science but also a visionary approach to public health and molecular research. With minor expansion in global engagement and translational outreach, Dr. Wang’s impact could be even more far-reaching. He is highly recommended for this honor.

Sherin Devaskar | Gene Regulation Epigenetics | Best Researcher Award

Published on by Cell Biologist

Prof. Sherin Devaskar | Gene Regulation Epigenetics | Best Researcher Award

Prof. Sherin Devaskar | UCLA | United States

Dr. Sherin U. Devaskar is a Distinguished Professor of Pediatrics at UCLA and the Executive Director of the Children’s Discovery and Innovation Institute. Renowned for her work in neonatology and developmental biology, Dr. Devaskar has committed her scientific career to unraveling how intrauterine environments influence neonatal and long-term offspring outcomes. Her research spans cellular, molecular, genetic, epigenetic, and physiological mechanisms, specifically focusing on placental biology and metabolic programming. As a leader in her field, she combines clinical excellence with groundbreaking research, translating findings into improvements in pediatric care. She has been recognized nationally for her academic contributions, holding memberships in elite institutions like the National Academy of Medicine. Dr. Devaskar’s research has had a significant impact on public health, particularly in understanding how early life exposures affect lifelong health trajectories. Her translational work bridges laboratory insights with population-based outcomes, making her a respected authority in developmental and environmental health research.

Publication Profiles: 

Scopus
Google Scholar

Education:

Dr. Sherin Devaskar began her medical training at Madras Medical College, India, where she earned her M.B.B.S./M.D. in Medicine. She pursued an Internship in Pediatrics (PL1) at the Institute of Child Health, Madras, completing. Seeking advanced clinical training, she moved to the United States and completed a Residency in Pediatrics (PL1 & PL2) at Wayne State Affiliated Hospitals, Detroit, MI. This strong foundation in both Indian and American medical systems gave her a global perspective in pediatrics. Over time, she augmented her clinical training with postdoctoral research and academic development, evolving into a globally recognized expert in neonatal and pediatric medicine. Her education laid the groundwork for a lifelong pursuit of excellence in child health and developmental research, fostering interdisciplinary collaboration across medicine, epidemiology, nutrition, and molecular biology.

Experience:

Dr. Devaskar has more than four decades of experience in pediatric medicine, specializing in neonatology and developmental biology. She currently holds the title of Distinguished Professor of Pediatrics at UCLA and serves as the Executive Director of both the Children’s Discovery and Innovation Institute and the Neonatal Research Center. Throughout her career, she has bridged clinical practice with scientific inquiry, directing major NIH-funded projects and mentoring the next generation of physician-scientists. Her work spans bench-to-bedside research on maternal-fetal health, metabolic programming, and placental function. She has held leadership roles in various pediatric research networks and has served on advisory boards for national health agencies. Her professional experience is distinguished not just by volume but also by the interdisciplinary and translational nature of her work. Dr. Devaskar is also a committed educator, having trained countless medical students, residents, and fellows who now contribute meaningfully to pediatric research and care worldwide.

Awards and Honors:

Dr. Sherin Devaskar’s pioneering contributions to pediatric medicine and research have earned her numerous prestigious awards. Most notably, she received the American Pediatric Society John Howland Award, the highest honor in academic pediatrics, recognizing her lifetime achievements in research, education, and leadership. She was honored with the Outstanding Scientific Accomplishments Award by the ATMA Association. Her election to the National Academy of Medicine further highlights her stature among the leading medical scientists in the world. These accolades reflect her sustained commitment to advancing pediatric health through rigorous science, innovation, and mentorship. In addition to these national honors, she is regularly invited to speak at international conferences, review NIH grants, and contribute to influential scientific panels. Her recognition underscores a career dedicated not only to scientific discovery but also to improving the lives of children globally through compassionate, evidence-based care.

Research Focus:

Dr. Devaskar’s research centers on the impact of intrauterine and early-life exposures on fetal and neonatal development, with an emphasis on placental biology, metabolic imprinting, and epigenetic regulation. Her multidisciplinary approach integrates molecular biology, environmental health, physiology, and neonatology, making her a leader in unraveling how prenatal environments shape long-term health outcomes. She has investigated the effects of air pollutants, nutritional mismatches, and oxidative stress on pregnancy outcomes and infant development. Her studies incorporate animal models, human cohorts, and placental tissue analyses to uncover biomarkers and molecular pathways that could be targeted for interventions. Notably, she explores placental resilience, especially under extreme stressors like COVID-19 or urban pollution. Dr. Devaskar’s work has direct translational relevance, offering insight into preventative strategies and therapeutic solutions for adverse pregnancy outcomes, pre-eclampsia, and neonatal hypoglycemia. Her research is frequently published in top-tier journals and is influential in shaping maternal-child health policies.

Publications Top Notes: 

  1. Diet, polycyclic aromatic hydrocarbons, and oxidative stress biomarkers in pregnancy: A Los Angeles pregnancy cohort

  2. Pediatric subspecialty workforce: what is needed to secure its vitality and survival?

  3. Does Amsterdam criteria applied to largely unsubmitted term placentas with favorable fetal outcomes show significant maternal clinicopathologic correlation?

  4. Exploring the long-term impacts of neonatal hypoglycemia to determine a safe threshold for glucose concentrations

  5. Hepatic and Pancreatic Cellular Response to Early Life Nutritional Mismatch

  6. Ambient exposure to fine particulate matter with oxidative potential affects oxidative stress biomarkers in pregnancy

  7. Placental Privilege: Evidence of organ resilience in severe COVID-19 in pregnancy

  8. Omega-3 reverses the metabolic and epigenetically regulated placental phenotype acquired from preconceptional and peri-conceptional exposure to air pollutants

  9. Urinary polycyclic aromatic hydrocarbon metabolites and their association with oxidative stress among pregnant women in Los Angeles

  10. Circulating extracellular vesicular microRNA signatures in early gestation show an association with subsequent clinical features of pre-eclampsia

Conclusion:

In conclusion, Dr. Sherin U. Devaskar is an outstanding candidate for the Best Researcher Award, with a remarkable blend of research excellence, leadership, and clinical relevance. Her contributions to understanding fetal and placental programming, particularly in the context of environmental exposures and metabolic health, have advanced the field in both depth and scope. Her dedication to interdisciplinary methods and translational science positions her as a thought leader in pediatric and perinatal research. Although greater global engagement and public science dissemination could enhance the reach of her work, these are growth areas rather than gaps. The breadth of her expertise, combined with her history of academic leadership and award-winning research, make her not only deserving of this recognition but also a role model for future generations of physician-scientists. Recognizing Dr. Devaskar with this award would honor a career built on scientific rigor, innovation, and a lifelong commitment to improving child and maternal health worldwide.

Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Raphael Borie | Gene Regulation Epigenetics | Best Researcher Award

Prof. Dr. Raphael Borie, APHP, France

Dr. Raphaël Borie, born on August 15, 1977, in Paris, France, is a leading expert in pulmonology and genetic respiratory diseases. Currently a University Professor Hospital Practitioner at Bichat Hospital (Paris Cité University), he has consistently contributed to the advancement of respiratory medicine, particularly in the field of interstitial lung diseases (ILDs). His clinical insight, combined with a strong research portfolio, has positioned him as a prominent figure within the OrphaLung network. A dedicated family man with two children, Dr. Borie is widely respected for his integrity, leadership, and commitment to collaborative medicine. His career reflects a unique blend of academic excellence and impactful translational research, bridging the gap between genomics and clinical care in ILD. He is a registered member of the French Medical Council (Ordre des Médecins No. 75/71138), and his research has influenced European clinical guidelines and improved the understanding of rare genetic pulmonary conditions.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Robust Academic Background:
    Dr. Borie holds a PhD in Genetics, Master’s in Physiology, and HDR (habilitation to supervise doctoral research), which underlines his scientific credibility and ability to lead independent research.

  2. Clinical-Research Integration:
    As a University Professor and Hospital Practitioner, he merges frontline patient care with cutting-edge genetic and respiratory disease research.

  3. High Publication Impact:
    With 283 PubMed-indexed articles and an H-index of 60, Dr. Borie’s work demonstrates strong citation influence, indicating widespread recognition and utility in the scientific community.

  4. International Leadership:
    Active in multinational collaborations (e.g., OrphaLung, ERS), he has co-authored major position statements and clinical trials, influencing European respiratory care guidelines.

  5. Innovation in Rare Diseases:
    A recognized expert in familial interstitial lung disease and telomere disorders, his work has led to earlier diagnosis and targeted therapies—critical in fields where few experts exist.

  6. Recognition and Funding:
    He has secured prestigious mobility grants (ERS, Respirology Teachers College)—a marker of trust in his scientific mission and innovation.

🔍 Areas for Improvement:

  • Wider Public Health Translation: While Dr. Borie’s genomic research is exceptional, expanding into real-world health policy implementation could enhance systemic impact.

  • Patient Engagement & Advocacy: Developing patient-oriented tools or registries (e.g., digital apps or platforms for familial lung diseases) may broaden his outreach beyond academia and clinics.

  • Broader Visibility: Although highly cited in professional circles, participation in international keynote talks, editorial leadership, or mainstream health media could elevate his public and professional visibility.

🎓 Education:

Dr. Borie has pursued an extensive and rigorous academic path focused on respiratory and genetic medicine. He obtained his medical degree with specialization in Allergology and Immunopathology in 2006. A year earlier, in 2005, he earned a Master’s degree in Biology and Physiology of Circulation and Respiration. Demonstrating deep interest in genetics, he completed a PhD in Genetics in 2017, contributing significantly to our understanding of genetic underpinnings in pulmonary fibrosis. In 2019, Dr. Borie achieved the prestigious Habilitation à Diriger des Recherches (HDR) from the University of Paris 7, enabling him to supervise doctoral research. His academic background illustrates a powerful integration of clinical expertise and molecular research—providing him with the tools to lead innovative research projects at the intersection of genomics and pulmonology.

🩺 Experience:

Dr. Raphaël Borie has over 15 years of experience in respiratory medicine. From July 2011 to August 2020, he served as a Hospital Practitioner in the Pneumology Department at Bichat Hospital under Professors Aubier and Crestani. Since September 2020, he has been a University Professor Hospital Practitioner in the same department, affiliated with Paris Cité University. He has contributed to patient care, education of medical students and residents, and cutting-edge research. As part of the OrphaLung network, he plays a critical role in advancing diagnostic tools and treatment approaches for rare lung diseases. He is recognized for his collaborative leadership and interdisciplinary contributions across genetics, immunology, and pulmonology. His international collaborations and authorship of over 280 PubMed-indexed publications demonstrate his ongoing commitment to improving patient outcomes through translational research.

🏆 Awards and Honors:

Dr. Borie’s research excellence has been recognized through several prestigious awards and scholarships. In 2017, he received the European Respiratory Society (ERS) Mobility Grant for his work on Identification of Preclinical Markers of Pulmonary Fibrosis, supporting international collaboration and advanced training. The same year, he was also honored with the Respirology Teachers College Mobility Grant, reinforcing his pioneering research on early detection of fibrotic lung disease. His selection for these awards highlights both scientific innovation and dedication to knowledge exchange. His leadership in multi-center studies and involvement in ERS guideline statements further reflect his status as a thought leader in interstitial lung disease. These honors are a testament to his influence in shaping the future of pulmonary genetics and translational respiratory medicine.

🔬 Research Focus:

Dr. Raphaël Borie’s research centers on familial and genetic interstitial lung diseases, particularly the molecular mechanisms behind pulmonary fibrosis, telomere biology, surfactant-related gene variants, and early detection strategies. He works extensively on identifying genetic risk variants (e.g., MUC5B, DSP) and their implications in idiopathic pulmonary fibrosis. Through his participation in the OrphaLung network, he supports genomic screening for hereditary lung disorders and contributes to developing European guidelines. His work bridges genomic medicine and clinical pulmonology, aiming for earlier diagnosis and personalized treatment approaches. He has led and co-authored critical studies on RTEL1 mutations, telomerase complex defects, and familial ILD phenotypes, helping clinicians globally understand the heterogeneity and systemic implications of genetic lung disorders. His collaborative international research ensures his findings are applied in practice to optimize long-term patient care.

📚Publications Top Notes:

  • 🧬 High risk of lung cancer in surfactant-related gene variant carriers – Eur Respir J, 2024

  • 📄 European Respiratory Society Statement on Familial Pulmonary Fibrosis – Eur Respir J, 2022

  • 🧪 Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants – Am J Respir Crit Care Med, 2022

  • 🧬 RTEL1 mutations and their phenotypic variability – Eur Respir J, 2019

  • 💊 Safety and efficacy of pirfenidone in telomerase mutation carriers – Eur Respir J, 2018

  • 🌐 Diagnosis and follow-up of familial ILD: International survey – BMC Pulmonary Med, 2025

  • 🧬 New 2023 ACR/EULAR APS criteria performance in young patients – Letter, 2025

  • 🫁 A non-resolving cough: a case of familial pulmonary fibrosis – Breathe, 2025

  • 🧬 PFMG2025: Genomic medicine in French healthcare system – Review, 2025

  • 💊 Efficacy of CFTR modulators in ABCA3-deficiency ILD – Open Access, 2025

  • 🧠 Neurological manifestations in VEXAS syndrome – Journal of Neurology, 2025

  • 💉 Real-life use of PEXIVAS reduced-dose regimen in vasculitis – Ann Rheum Dis, 2025

  • 🧫 Recurrent respiratory papillomatosis with lung involvement – Eur Respir J, 2025

  • 🔍 RA-ILD: genetics to clinical overview – Review, 2025

  • 👶 Childhood ILD survivors in adulthood: European study – Eur Respir J, 2025

🧾 Conclusion:

Dr. Raphaël Borie exemplifies the ideal candidate for the Best Researcher Award. His excellence spans across clinical expertise, academic distinction, and international research leadership, especially in genetic and familial interstitial lung diseases—a field with enormous unmet need. His consistent scholarly output, impactful collaborations, and patient-focused studies highlight a unique blend of depth and innovation. While further expansion into public health frameworks and patient engagement tools would be valuable, his profile already reflects a world-class researcher with transformative contributions to pulmonary medicine.

Zhirong Tan | Gene Regulation Epigenetics | Best Researcher Award

Published on by Cell Biologist

Prof. Zhirong Tan | Gene Regulation Epigenetics | Best Researcher Award

Prof. Zhirong Tan  , Xiangya Hospital, Central South University , China

Professor Zhirong Tan is a leading Chinese expert in pharmacogenomics and clinical pharmacology. Currently a professor at Xiangya Hospital, Central South University, he also serves as the Director of the Pharmacogenetics and Pharmacokinetics Research Laboratory and Deputy Director of the Drug Analysis Center. He has been instrumental in over 300 clinical trials, pushing forward the frontiers of precision medicine, especially in colorectal cancer and Alzheimer’s disease. With over 20 SCI papers, multiple patents, and co-authorship of four books, he’s widely recognized for his work in pharmacokinetics and biomarker discovery. A national GCP and GMP inspector, Prof. Tan actively contributes to pharmaceutical regulation and innovation in China. His academic and industry partnerships reflect a robust foundation in translational research and real-world drug development.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Prof. Zhirong Tan has made outstanding contributions to clinical pharmacology, pharmacogenetics, and metabolomics over two decades. His research has provided critical insights into drug metabolism, biomarker discovery, and precision medicine, especially in colorectal cancer and Alzheimer’s disease.

  2. Prolific Publication Record
    With over 22 SCI-indexed publications (first or corresponding author) and 6 CSCD papers, Prof. Tan’s research has achieved over 3550 citations and an H-index of 33 on Web of Science—evidence of the high impact and recognition of his work.

  3. Strong National & Industry Collaborations
    He has participated in or led 300+ clinical trials and secured 5 “Million+” industry-funded projects, reflecting strong ties with both academia and industry. His leadership in national-level projects, such as the “Major New Drug Development” program, showcases his influence in China’s healthcare innovation.

  4. Intellectual Property and Innovation
    With 3 granted patents and 3 under review, Prof. Tan’s ability to translate research into practical applications is evident. His individualized esomeprazole dosing regimen highlights innovation at the clinical level.

  5. Regulatory & Policy Contributions
    As a national GCP/GMP inspector, he plays a pivotal role in drug trial ethics and compliance in China. He also holds leadership roles in pharmacogenomics committees, further demonstrating his commitment to public health advancement.

  6. Academic Mentorship and Editorial Work
    In addition to research, Prof. Tan contributes as a journal reviewer, co-author of four textbooks, and mentor to the next generation of scientists, reinforcing his role as a thought leader in the field.

🔍 Areas for Improvement:

  1. International Visibility
    While Prof. Tan’s national presence is remarkable, further international collaborations, invited keynotes at global conferences, or leading roles in global consortia could enhance his visibility and expand the influence of his work.

  2. Broader Publication Range
    Publishing more frequently in top-tier international journals (e.g., Nature, The Lancet, NEJM) would increase the global academic reach of his findings.

  3. Open Science & Data Sharing
    As the field moves toward transparency, incorporating open-access publications and shared data repositories could boost both reproducibility and citations.

🎓 Education:

Professor Zhirong Tan obtained his Ph.D. from Central South University, a premier Chinese institution, where he laid the groundwork for his expertise in clinical pharmacology and pharmacogenomics. He later pursued postdoctoral research at the School of Pharmacy, University of Maryland, Baltimore, one of the top pharmaceutical research institutions in the United States. This international experience enabled him to gain a global perspective in drug metabolism, biomarker identification, and translational pharmacology. His academic training focused on cutting-edge methodologies such as metabolomics, pharmacokinetics, and precision medicine. Through continuous education and research, he has built a reputation as a highly skilled pharmacologist whose work bridges basic research and clinical applications.

💼 Experience:

With a research career spanning over two decades since 1998, Professor Zhirong Tan has led and participated in numerous national-level and provincial-level projects, including China’s National Science and Technology Major Projects. He currently holds multiple leadership positions at Xiangya Hospital, Central South University. Over the years, he has completed major research grants from NSFC, the Hunan Province, and the Ministry of Science and Technology. As a GCP and GMP inspector, Prof. Tan has overseen more than 300 clinical trials, ensuring drug development meets regulatory and ethical standards. His experience also extends to industry collaboration, with successful execution of 5 “Million+” funded projects and influential roles in pharma-academic alliances. A frequent peer reviewer and contributor to international journals, his work influences both the scientific community and regulatory frameworks.

🔬 Research Focus:

Professor Tan’s primary research focus lies in clinical pharmacology, pharmacogenomics, and metabolomics, particularly for colorectal cancer and Alzheimer’s disease. His work aims to identify and validate biomarkers for disease diagnosis, drug efficacy, and toxicity prediction. A major contributor to China’s “Major New Drug Development” initiative, he has developed personalized esomeprazole dosing regimens by studying genetic polymorphisms, SNPs, and microRNA interactions. His research also explores the pathogenesis of Alzheimer’s disease using metabolomic profiling, offering insights into early detection and potential therapeutics. He applies advanced bioanalytical methods to understand inter-individual variability in drug metabolism and therapeutic response. His projects have real-world clinical implications, transforming how drugs are prescribed, regulated, and monitored. Through his pioneering work, Prof. Tan contributes significantly to the evolution of precision medicine in China.

📚 Publication Top Notes:

  1. 📊 Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

  2. ❤️ Gly389Arg polymorphism of β1‐adrenergic receptor and cardiovascular response to metoprolol

  3. 💊 CYP2C19 ultra-rapid metabolizer genotype affects voriconazole pharmacokinetics

  4. 🧬 HLA‐B35:01 allele as biomarker for Polygonum multiflorum–induced liver injury*

  5. 🌿 Repeated berberine administration inhibits cytochromes P450 in humans

  6. 💉 Effect of SLCO1B1 polymorphism on pharmacokinetics of nateglinide

  7. 🧪 Assessment of cytochrome P450 activity by five‐drug cocktail approach

  8. ☕ Plasma caffeine metabolite ratio linked to CYP1A2 polymorphisms

  9. 🔬 Inducibility of CYP1A2 by omeprazole associated with genetic polymorphism

  10. 🧫 Ile118Val polymorphism of CYP3A4 affects simvastatin lipid-lowering efficacy

📝 Conclusion:

Professor Zhirong Tan is a highly deserving candidate for the Best Researcher Award. His record of scientific excellence, clinical innovation, and regulatory leadership clearly positions him as a key contributor to modern pharmacology. His integrated approach—spanning basic science, clinical trials, and health policy—has had a measurable impact on patient care and drug development in China.

While there is room to further expand his global footprint, his accomplishments to date already demonstrate the caliber, commitment, and consistency expected of a world-class researcher.